Recent Updates
Recently added Catalysts

CYB003

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |Cybin Inc.|Last Updated: May 6, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials3
Total Enrollment745
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06605105Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)PHASE3 ENROLLING BY_INVITATION 468Jul 18, 2025Mar 15, 2028Mar 11, 202619 United States
NCT06564818"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"PHASE3 RECRUITING 220Dec 17, 2024Sep 1, 2026May 6, 202646 United States
NCT05385783A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive DisorderPHASE1 COMPLETED 57Aug 2, 2022Jan 18, 2024Mar 25, 20243 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Montgomery-Asberg Depression Rating Scale (MADRS)
Baseline, Day 28, Day 56, Day 84, Day 112, Day 140, Day 168, Day 196, Day 244, Day 252, Day 280, Day 301; additional assessments at Day -15, Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 42 if non-response or relapse criteria met

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phrased questions about symptoms to more detailed ones allowing a precise rating of severity. The scale consists of ten items rated on a scale from 0 to 6, resulting in a total score ranging from 0 (normal / symptom absent) to 60 (severe depression).

Montgomery-Åsberg Depression Rating Scale (MADRS)
Screening Day-45, Baseline Day-1, Day 2, Day 10, Day 21, Day 23, Day 31, and Day 42 (End of Treatment)

The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phrased questions about symptoms to more detailed ones allowing a precise rating of severity.

Adverse Events (All Arms)
Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E)

Any untoward medical occurrence in a clinical investigation participant administered a drug and does not necessarily have a causal relationship with the treatment

Resting 12 Lead ECG ventricular rate (Arms A & B)
Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23

ventricular rate (beats per minute)

Resting 12 Lead ECG ventricular rate (Arms C & D)
Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

ventricular rate (beats per minute)

Resting 12 Lead ECG ventricular rate (Arms E)
Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

ventricular rate (beats per minute)

Resting 12 Lead ECG PR interval (Arms A & B)
Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

PR interval (milliseconds)

Resting 12 Lead ECG PR interval (Arms C & D)
Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

PR interval (milliseconds)

Resting 12 Lead ECG PR interval (Arms E)
Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

PR interval (milliseconds)

Resting 12 Lead ECG QRS duration (Arms A & B)
Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

QRS duration (milliseconds)

Resting 12 Lead ECG QRS duration (Arms C & D)
Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

QRS duration (milliseconds)

Resting 12 Lead ECG QRS duration (Arms E)
Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

QRS duration (milliseconds)

Resting 12 Lead ECG QT interval (Arms A & B)
Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

QT interval (milliseconds)

Resting 12 Lead ECG QT interval (Arms C & D)
Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

QT interval (milliseconds)

Resting 12 Lead ECG QT interval (Arms E)
Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

QT interval (milliseconds)

Resting 12 Lead ECG QTcF (Arms A & B)
Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23

Corrected QT interval by Fredericia (milliseconds)

Resting 12 Lead ECG QTcF (Arms C & D)
Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9

Corrected QT interval by Fredericia (milliseconds)

Resting 12 Lead ECG QTcF (Arms E)
Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16

Corrected QT interval by Fredericia (milliseconds)

Holter monitoring (Arms A & B)
Day -1, Day 1, Day 22

Record of the electrical activity of the heart (Hz)

Holter monitoring (Arms C & D)
Day -1, Day 1, Day 8

Record of the electrical activity of the heart (Hz)

Holter monitoring (Arm E)
Day -1, Day 1, Day 8, Day 15

Record of the electrical activity of the heart (Hz)

Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms)
Screening

Evaluation tool that evaluates a lifetime history of suicidal ideation and/or behavior. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B)
Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56

Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D)
Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28

Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E)
Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35

Evaluation tool that evaluates risk for suicide since the last study visit. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of actual attempts are rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care).

Secondary Endpoints
The Beck Depression Inventory-Second Edition (BDI-II)
Baseline Day-1, Day 21, and Day 42 (End of Treatment)
The Clinical Global Impression Scale (CGI-S)
Screening Day-45, Baseline Day-1, and Day 42 (End of Treatment)
The Generalized Anxiety Disorder 7-item scale (GAD-7)
Baseline Day-1, Day 21, and Day 42 (End of Treatment)
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
CYB003EXPERIMENTALInitial non-responders in CYB003-002 APPROACH and CYB003-003 EMBRACE, or initial responders who later relapse will be eligible to receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. If a participant relapses again, the participant may receive an additional single 16mg of CYB003 (maximum of 3 16mg doses in CYB003-004 EXTEND). Participants will continue on their current antidepressants and receive psychological support throughout the study.
Experimental Arm A: CYB003 in 2 of 2 Dosing SessionsEXPERIMENTALArm A participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.
Placebo Comparator Arm B: Placebo in 2 of 2 Dosing SessionsPLACEBO_COMPARATORArm B participants will receive placebo in 2 of 2 Dosing Sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.
A: MDD Participants - CYB003 in 2 of 2 Medicine SessionsEXPERIMENTALArm A MDD participants will receive CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
B: MDD Participants - Placebo in Medicine Session 1, CYB003 in Medicine Session 2PLACEBO_COMPARATORArm B MDD participants will receive placebo in Medicine Session 1, and approximately three weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All MDD participants will receive supportive EMBARK psychotherapy throughout the study.
C: Healthy Volunteers - CYB003 in 2 of 2 Medicine SessionsEXPERIMENTALArm C healthy volunteers will receive CYB003 in 2 of 2 medicine sessions, approximately one to two weeks apart. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
D: Healthy Volunteers - Placebo in Medicine Session 1, CYB003 in Medicine Session 2PLACEBO_COMPARATORArm D healthy volunteers will receive placebo in Medicine Session 1, and approximately one to two weeks later will receive CYB003 in Medicine Session 2. The CYB003 dose received will depend on the cohort/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
E: Healthy Volunteers - CYB003 in 3 of 3 Medicine SessionsEXPERIMENTALArm E healthy volunteers will receive CYB003 in 3 of 3 medicine sessions, approximately one week apart from each other, to assess bioavailability and food effect. The CYB003 dose received will depend on the safety review committee selection/time of enrollment. All healthy volunteers will receive psychological support throughout the study.
Interventions
NameTypeDescription
CYB003DRUGCYB003 is a deuterated psilocin analog
Psychological SupportBEHAVIORALManualized psychological support performed by facilitators
PlaceboDRUGPlacebo
PsychotherapyBEHAVIORALManualized psychotherapy (called EMBARK) performed by facilitators
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 85 Years
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: * Has successfully completed either CYB003-002 APPROACH or CYB003-003 EMBRACE and received both dose administrations of trial medication * Has continued the same antidepressant medication at the stable dose/day throughout CYB003-002 APPROACH or CYB003-003 EMBRACE * Has provided ...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06564818primaryCompletionDate: changed
LOWMay 26, 2026NCT06605105primaryCompletionDate: changed
LOWMay 24, 2026NCT06564818studyFirstPostDate: changed
LOWMay 24, 2026NCT06605105studyFirstPostDate: changed